Clinical Trial Update: CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating cytomegalovirus immune globulin (CMVIG) prophylaxis in belatacept-converted kidney transplant recipients to prevent CMV…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Kidney Transplantation

Drugs mentioned

• CMV Immune Globulin (cytomegalovirus immune globulin)
• belatacept (belatacept)

Snippet

Sponsor: University of Minnesota | Conditions: Kidney Transplant; Complications, CMV | Phase 1, Phase 2 | Status: RECRUITING